HTB South

Paediatric care

Earlier ART reduces infant mortality in South Africa but risk of death and loss to follow up still high

Chewable raltegravir tablets can be crushed and dispersed in liquid for young children

Dolutegravir exposure increases when fixed dose combination tablets are crushed

Pharmacokinetics, safety and efficacy of dolutegravir in very young children

Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants

Tenofovir alafenamide exposure modestly higher in children than adults

VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding

World Health Organisation paediatric dosing tool

FDA approves raltegravir for newborns

Long-acting ART for children is a deferred priority despite achievable dosing

PROMISE results support WHO recommendations for pregnant and breastfeeding women: more needs to be done to improve ART acceptability and adherence

Raltegravir-based third-line ART in children and adolescents

No increased resistance with once daily dosing of abacavir and 3TC than twice daily dosing in the ARROW trial

Raltegravir in HIV-exposed neonates

Virological response without routine viral load monitoring in children: results from the ARROW trial

Tenofovir-containing ART reduces bone mineral density in breast feeding women: results from IMPAACT P1084s

Shortened nine-month MDR-TB treatment works well in children and adolescents

Levofloxacin: safety and tolerability in HIV positive and negative children treated for MDR-TB

Point of care HIV PCR test for infant diagnosis: good performance but poorer results in youngest age group

Weekend-off ART is non-inferior to continuous ART in young people taking efavirenz-based regimens: results from BREATHER study

Increased cardiovascular risks in HIV positive children in Uganda and Zambia partially reversed by ART

Lopinavir/ritonavir in young children is superior to nevirapine after five years: results from long term follow up of IMPAACT P1060

Long-term safety and efficacy of tenofovir in children

Drug resistance in children after PMTCT and early treatment

Update on paediatric antiretrovirals

Is d4T a viable option for children in low-income countries?

3TC or FTC monotherapy suboptimal as a bridging strategy for adolescents

Rationalising the paediatric antiretroviral formulary in Malawi

Time to first-line failure in the IeDEA cohort

Influence of early ART on antibody detection in children

Paediatric pipeline: CROI 2014 update on new antiretrovirals for children

Efavirenz maintenance therapy effective in children exposed to nevirapine prophylaxis

Trials show further benefits for cotrimoxazole in children and adults

FDA approves raltegravir for children older than 4 weeks

Lower immune response to the qHPV vaccine in HIV positive girls

HIV exposed vs unexposed babies have lower gestational age and birth weight in Danish study

Outcomes in infants exposed to lopinavir/ritonavir in utero

WHO 2013 guidelines: what about the missing formulations?

Decreased growth in ART exposed uninfected infants in Botswana

Antiretrovirals, doses and formulations for children

Five-year results from the AntiRetroviral Research for Watoto (ARROW) Trial

Comparison of ritonavir-boosted lopinavir or NNRTI ART and PK with antimalarials in Ugandan children

Pharmacokinetics and acceptability of lopinavir/ritonavir sprinkles in children aged 1 to 4 years

Pharmacokinetics of currently available antiretroviral options for young children

Tenofovir use in children

ddI resistance in South African children failing an abacavir or d4T based first-line regimen

Report of a functional cure in an HIV infected infant

Paediatric TB: glimpses of PK data and a potential new approach to drug development

New UNITAID grants focus on paediatric HIV, TB and malaria

US paediatric guidelines updated

Resistance in infants and children receiving ART in South Africa

ART and adverse birth outcomes in Botswana

Antiviral activity in vitro with S/GSK1265744

Paediatrics studies at 19th International AIDS Conference and the 4th International Workshop on HIV Pediatrics

Novel lopinavir/ritonavir sprinkle formulation for children in resource-limited settings

Update on new antiretrovirals for children and adolescents

Tenofovir prophylaxis for neonates

Efavirenz levels variable in children in the CHAPAS-3 study

Lipid profile in children in PREDICT: immediate versus deferred nevirapine-based ART

High prevalence of peripheral neuropathy in children taking d4T in rural South Africa

BCG vaccination at birth induces CD4 cell activation in HIV exposed infants

Paediatric formulations of ARVs: including an exciting new class

Lower malaria risk in children receiving lopinavir/ritonavir-based compared to NNRTI-based ART

High prevalence of d4T-associated lipodystrophy including lipoatrophy in children

Lopinavir/ritonavir monotherapy in children

Post navigation